Table 1 Parameters used for input into a model of cost-effectiveness of tenofovir for PMTCT in South Africa, based on a simulated cohort of 10,000 antenatal women and their babies
Parameter | Point estimate | Uncertainty (Lower bound - Upper bound) | Source (references) |
|---|---|---|---|
p1: Probability of mother being HBsAg+ | 3.6% | 3.1–7.4%b | |
p2: Probability of mother who is HBsAg+ being HBeAg+ | 23% | 16.7–42.9%b | |
p3: Probability of mother who is HBsAg+ and HBeAg+ having child who is HBsAg+ (no PMTCT) | 38.3% | 7.0–74.4%b | [22] |
p4: Probability of mother who is HBsAg+ and HBeAg- having child who is HBsAg+ (no PMTCT) | 4.8% | 0.1–13.3%b | [22] |
Relative risk reduction (efficacy) of TDF | 71% | 26–89% | [15] |
Antiviral adherence | 73.5% | 69.3–77.5% | [28] |
S2: Cost of diagnostics: laboratory test for HBsAg | $9.1 per mother | Â | [29] |
S3: Cost of diagnostics: laboratory test for HBsAg and HBeAg | $9.1 per mother (HBsAg test) + $9.1 for HBsAg+ mother (HBeAg test) |  | [29] |
S2: Cost of diagnostics: POCT for HBsAg | $2 * all mothers | Â | [29] |
S3: Cost of diagnostics: POCT for HBsAg+ and laboratory test for HBeAg+ | $2 * for all mothers (HBsAg test) + $ 9.1 * for all HBsAg+ mothers (HBeAg test) |  | [29] |
Treatment cost: monthly cost of TDF, applied to all HBsAg+ women (S2) or only to HBsAg+/HBeAg+ women (S3) | $2.48a/month | Â | [30] |
POCT sensitivity | 97.6% | Â | [21] |
Estimated relative risk reduction (efficacy) of TDF when combined with birth dose vaccine and HBIg | 90% | 85–95% | [9] |
Prevalence of TDF resistance | 0.08% | Â | [31] |